Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Recursion Pharmaceuticals’ latest earnings call struck a cautiously optimistic tone as management highlighted its first AI-enabled clinical proof-of-concept, major cost cuts, and an extended cash ...

Some books move forward. Others circle. "Paradiso 17" by Hannah Lillith Assadi and "Python's Kiss" by Louise Erdrich belong to the second camp, less interested in where a story ends than in how it ...

Stop piping grep into five other commands. It already handles most of that.

Infosecurity outlines key recommendations for CISOs and security teams to implement safeguards for AI-assisted coding ...

过去一两年，ChatGPT 等 AI 聊天工具凭借强大信息处理能力，成为工作中的 “万能顾问”，高效搞定写邮件、解疑问等需求。但面对业务执行场景，它们暴露短板：仅能提供方案，缺乏行动力、无法集成内部系统、难串联复杂流程，始终是 ...